Medidata Launches Sensor Cloud, Ushering in Next Generation Solution for Connected Devices and Wearable Sensors in Clinical Trials

• Unified solution simplifies and expedites sensor integration, data ingestion and analysis, and digital biomarker discovery
• New technology will generate intelligent insights and help improve clinical outcomes

New York, New York – February 8, 2020 – Medidata, a Dassault Systèmes company, today announced the launch of Sensor Cloud, a transformative platform for managing a broad range of sensor and digital health technology data during the clinical trial process. Sensor Cloud seamlessly integrates with Medidata Rave Clinical CloudTM and supports continuous patient data collection from both Medidata and third-party medical-grade sensors. This innovation will provide a broader and deeper view into the patient experience.  
 
“With the ability to measure a wide variety of biometric data including vital signs, movement, sleep patterns and more, Sensor Cloud presents an unparalleled opportunity for researchers to derive new insights from vast amounts of data,” said Anthony Costello, president, Patient Cloud at Medidata. “As sensor usage in clinical trials is projected to surge up to 70% by 20251, it is imperative that we create the platform needed to rapidly standardize and integrate sensor data in order to harness the full power of these technologies for the benefit of patients.”
 
Following Medidata’s recent acquisition of digital biomarker business MC10, the launch of Sensor Cloud further strengthens the company’s unique data ingestion, analytics and insights capabilities that currently provide differentiated value to patients, trial sites, trial sponsors and contract research organizations (CROs). Using Sensor Cloud, researchers can access sensor data through a single Application Programming Interface (API, a software intermediary that allows two applications to talk to each other) and integrate new sensor technologies in weeks rather than months. Sensor Cloud provides the ability to:

• Enable greater insights through proprietary analytics including novel digital biomarker discovery 
• Lower costs and enable greater operational efficiency by making it easier for patients to share data and stay enrolled in trials
• Standardize data from ingestion through delivery via a common data model
• Reduce site and patient burden by cutting down on-site visits, time, and travel through a more flexible engagement model

“Social distancing and other prevention protocols necessitated by the COVID-19 pandemic have greatly accelerated the adoption of remote technologies as a way to ensure the continuation of clinical trials,” added Costello. “These advancements will continue to grow in popularity, outlasting the pandemic and, as trials continue to improve and become more patient-centric, communication and engagement become increasingly important. Patient involvement and the quality of the data generated by sensors will be integral to the overall evolution of this innovative research model.”

In 2021, Medidata will continue to expand on its growing list of supported devices and sensors that includes BioStamp^Ⓡ, ActiGraph, and BioIntellisense^TM. This growing library of high fidelity connected devices in combination with Sensor Cloud's analytics will advance researchers' understanding of disease progression and treatment effects in the home, while enhancing the clinical trial experience for patients.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.